Drug Profile
Research programme: DNA-based monoclonal antibodies - infections - Inovio/AstraZeneca/University of Pennsylvania
Latest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator Inovio Pharmaceuticals; MedImmune; University of Pennsylvania
- Developer AstraZeneca; Inovio Pharmaceuticals; University of Pennsylvania
- Class Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Influenza virus infections; Pseudomonal infections; Staphylococcal infections
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (Intradermal)
- 28 Nov 2018 No recent reports of development identified for preclinical development in Pseudomonal-infections in USA (Intradermal)
- 28 Nov 2018 No recent reports of development identified for preclinical development in Staphylococcal-infections in USA (Intradermal)